Allopur 300 mg Norge - norsk - Statens legemiddelverk

allopur 300 mg

orifarm healthcare a/s - allopurinol - tablett - 300 mg

Allopur 100 mg Norge - norsk - Statens legemiddelverk

allopur 100 mg

orifarm healthcare a/s - allopurinol - tablett - 100 mg

Allopurinol Orion 300 mg Norge - norsk - Statens legemiddelverk

allopurinol orion 300 mg

orion corporation - espoo - allopurinol - tablett - 300 mg

Allopurinol Orion 100 mg Norge - norsk - Statens legemiddelverk

allopurinol orion 100 mg

orion corporation - espoo - allopurinol - tablett - 100 mg

Allopurinol Sandoz 100 mg Norge - norsk - Statens legemiddelverk

allopurinol sandoz 100 mg

sandoz - københavn - allopurinol - tablett - 100 mg

Allopurinol Sandoz 300 mg Norge - norsk - Statens legemiddelverk

allopurinol sandoz 300 mg

sandoz - københavn - allopurinol - tablett - 300 mg

Allopurinol Aristo 300 mg Norge - norsk - Statens legemiddelverk

allopurinol aristo 300 mg

aristo pharma gmbh - allopurinol - tablett - 300 mg

Allopurinol Aristo 100 mg Norge - norsk - Statens legemiddelverk

allopurinol aristo 100 mg

aristo pharma gmbh - allopurinol - tablett - 100 mg

Venclyxto Den europeiske union - norsk - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Duzallo Den europeiske union - norsk - EMA (European Medicines Agency)

duzallo

grunenthal gmbh - allopurinol, lesinurad - gikt - antigout preparater - duzallo er angitt i voksne for behandling av hyperuricaemia i gikt pasienter som ikke har oppnådd målet serum urinsyre med en tilstrekkelig dose av allopurinol alene.